The subject received any investigational treatment within the past 30 days or prior immunotherapy or antibody therapy within the past 45 days.
Pamolidomide: 7 days
Patients must be at least 28 days past their last course of lymphoma or CLL treatment, at least 84 days past their last course of rituximab treatment. Patients with pre-existing severe or life threatening side effects/conditions from prior therapy or due to other diseases may not be enrolled
Concomitant medications:\r\n* Growth factors that support platelet or white cell number of function must not have been administered within the past 7 days\r\n* Patients with CNS tumors who have not been on a stable or decreasing dose of dexamethasone for the past 7 days\r\n* Patients who are currently receiving another investigational drug\r\n* Patients who are currently receiving other anti-cancer agents\r\n* Allergy or intolerance to agents on this protocol: vincristine, irinotecan, temozolomide, or metformin\r\n* Allergy to cephalosporins\r\n* Patients who have uncontrolled infection, positive blood cultures within the past 48 hours, or receiving treatment for Clostridium difficile infection
No increase in steroid dose within the past 7 days
Significant clinical change in health in the past 30 days
No chemotherapy or radiotherapy within the past 28 days
Systemic antineoplastic therapy in the past 14 days (excluding hydroxyurea)
Concomitant medications: the following drugs need to be stopped at the time of beginning therapy: patient cannot be on liver enzyme inducing anticonvulsants; patients must not have received growth factors to support the number or function of white cells or platelets within the past 7 days and pegfilgrastim within the past 14 days; patients must not be receiving any anti-thrombotic or anti-platelet agents; patient cannot be on drugs that cause significant prolonged QT (category I drug)
Tumor staging by standard imaging within the past 30 days (Step 1 subjects only)
Subject has received chemotherapy within the past 28 days
Erythropoietin or related hormones must not have been administered within the past 28 days
Prior investigational therapy within the past 28 days.
Prior cell therapy for relapse within the past 90 days
Received no other investigational therapy within the past 14 days
Enrollment in other studies for any disease in the past 30 days
No increase in steroid dose within the past 7 days
No patients receiving other investigational therapy for the past 30 days before dosing.
Past or current anti-cancer treatment except corticosteroids of less than 7 days duration in total
Any investigational therapy in the past 30 days
Prior radiopharmaceutical therapy (e.g. radium-223, strontium-89, samarium-153, etc) within the past 30 days
Has the subject received any investigational treatment within the past 30 days?
any investigational treatment within the past 30 days
Any change in psychotropic medications in past 30 days
Reports a fall in the past 30 days
Non-cigarette tobacco use in the past 30 days
Reports a fall in the past 30 days
Patient-reported cigarette use within the past 30 days
Psychostimulant use in the past 30 days prior to registration
Recent quitters (have not smoked in past 7 days)
Use of laxatives within the past 7 days
Use of antibiotics within the past 7 days
Smoke on >= 25 days of the past 30 days
PILOT III: Has experienced fatigue within the past seven days
Smoke on >= 25 days of the past 30 days
Patients who are receiving any other investigational agents (in the past 28 days) or herbal medication (within 1 day)
Patients who are receiving any other investigational agents (in the past 28 days) or herbal medications (within 1 day)
Other tobacco use within the past year for 7 consecutive days or 14 times
Report tobacco use within the past 7 days
Patients who are receiving any other investigational agents (in the past 28 days) or herbal medications (within 7 days)
Participants must not have had chemotherapy within the past 10 days